Launch three biosimilar products in Israel

Deadline passed; outcome being checked

What the company said

“the three products are expected to be launched in Israel between 2022 and 2024”

SourceKamada Ltd. Form 6-K press release, 2021-01-13
FilingSEC filing index
Deadline as statedbetween 2022 and 2024
Deadline used31 Dec 2024, the last day of the stated period
TypeProduct
Permanent referenceKI-C-2021-KMDA-022010
Cite as https://keptindex.org/c/KI-C-2021-KMDA-022010/ — this address never changes.

The deadline has passed. We check for public evidence starting 30 days after the deadline, and repeat the check if nothing clear turns up.

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

Version 1 · original · stated 13 Jan 2021

Deadline 31 Dec 2024 (“between 2022 and 2024”) · wording expected
Version 2 · stated 10 Feb 2021

Deadline 31 Dec 2025 (“between 2022 and 2025”)

“Launching nine biosimilar products in the Israeli-based Distribution segment between 2022 and 2025, pending regulatory approval”
Source for this version

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Commercial launch
Indicative materiality: Medium rules
Action: Launch
Deliverable: three biosimilar products
Where: Israel
Language: Expected (“expects”, “plans”)
In the company’s control: Medium
Specificity: Medium
Conditional: Yes: Subject to approval by the European Medicines Agency (EMA) and subsequently by the Israeli Ministry of Health (IMOH)
Depends on: Regulatory

This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.

Commitment recordedThe company's words were matched word for word against the filing.
OutcomeNot yet assessed. Nothing is judged before the deadline.

Are you Kamada Ltd.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.